AC Immune SA
NASDAQ:ACIU
AC Immune SA
Interest Income Expense
AC Immune SA
Interest Income Expense Peer Comparison
Competitive Interest Income Expense Analysis
Latest Figures & CAGR of Competitors
Company | Interest Income Expense | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
AC Immune SA
NASDAQ:ACIU
|
Interest Income Expense
-CHf599k
|
CAGR 3-Years
5%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
N/A
|
|
ADC Therapeutics SA
NYSE:ADCT
|
Interest Income Expense
-$35.3m
|
CAGR 3-Years
-11%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
CRISPR Therapeutics AG
NASDAQ:CRSP
|
Interest Income Expense
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Basilea Pharmaceutica AG
SIX:BSLN
|
Interest Income Expense
-CHf9.5m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
N/A
|
|
Idorsia Ltd
SIX:IDIA
|
Interest Income Expense
-CHf21.9m
|
CAGR 3-Years
-278%
|
CAGR 5-Years
-64%
|
CAGR 10-Years
N/A
|
|
Kuros Biosciences AG
SIX:KURN
|
Interest Income Expense
-CHf155k
|
CAGR 3-Years
28%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
N/A
|
See Also
What is AC Immune SA's Interest Income Expense?
Interest Income Expense
-599k
CHF
Based on the financial report for Dec 31, 2023, AC Immune SA's Interest Income Expense amounts to -599k CHF.
What is AC Immune SA's Interest Income Expense growth rate?
Interest Income Expense CAGR 5Y
-15%
The average annual Interest Income Expense growth rates for AC Immune SA have been 5% over the past three years , -15% over the past five years .